CRA was commissioned by AstraZeneca to investigate the economic and societal burden associated with Acute Coronary Syndrome (ACS) in Canada. This short paper represents a summary of the full report.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...